Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $269000.0.

  • Enanta Pharmaceuticals' Other Non-Current Liabilities rose 1446.81% to $269000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $269000.0, marking a year-over-year increase of 1446.81%. This contributed to the annual value of $260000.0 for FY2025, which is 1255.41% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Other Non-Current Liabilities of $269000.0 as of Q4 2025, which was up 1446.81% from $260000.0 recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $994000.0 for Q1 2021, and its period low was $224000.0 during Q1 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' median Other Non-Current Liabilities value was $420000.0 (recorded in 2022), while the average stood at $476300.0.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Other Non-Current Liabilities surged by 5676.33% in 2023 and then crashed by 6515.84% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $856000.0 in 2021, then plummeted by 51.64% to $414000.0 in 2022, then surged by 56.76% to $649000.0 in 2023, then crashed by 63.79% to $235000.0 in 2024, then increased by 14.47% to $269000.0 in 2025.
  • Its Other Non-Current Liabilities was $269000.0 in Q4 2025, compared to $260000.0 in Q3 2025 and $252000.0 in Q2 2025.